Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.71 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | PRKACA | P17612 | 6/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027682 | 1.00 | AHCY (0.71) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL3016115 | 0.95 | AHCY (0.68) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL13211004 | 0.95 | AHCY (0.68) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL13211002 | 0.83 | AHCY (0.63) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL25047825 | 0.81 | AHCY (0.84) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL30941230 | 0.81 | AHCY (0.84) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL10001410 | 0.81 | PRKACA (0.83) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL31617851 | 0.79 | AHCY (0.83) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL25046624 | 0.79 | AHCY (0.83) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A | |
| SCHEMBL14178249 | 0.79 | ADORA3 (0.82) | AHCYHSP90B1HSP90AA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | AHCY 598/4885HSP90B1 1346/4885HSP90AA1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.